Internal Medicine, Medical Oncology · Chicago, IL
NPI
1437187929
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
675 N Saint Clair St, Galter 21-100
Chicago, IL, 60611
Phone (312) 695-0990
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
87,945 services
Medicare patients, 2024
431
Average age 73
Drug cost, 2024
$2.3M
687 prescriptions
Company payments, 2025
$58K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by William Gradishar was code J9358 (injection, fam-trastuzumab deruxtecan-nxki, 1 mg), 23,900 times for 17 patients. In total William Gradishar billed 87,945 services in 72 codes, and Medicare paid $1.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-07-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9358 Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | Office | 23,900 | 17 | $21.62 | $517K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 11,700 | 27 | $0.11 | $1,321 |
| J0897 Injection, denosumab, 1 mg | Office | 8,940 | 33 | $20.68 | $185K |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,460 | 28 | $5.86 | $8,552 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,320 | 38 | $0.09 | $119 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,060 | 36 | $0.70 | $743 |
| 99214 Office E&M - Established | Office | 616 | 330 | $92.42 | $57K |
| 96375 Injection Administration | Office | 239 | 44 | $12.46 | $2,977 |
| 96413 Chemotherapy Administration | Office | 210 | 65 | $104.91 | $22K |
| 96372 Injection Administration | Office | 96 | 39 | $11.64 | $1,117 |
| 96367 Intravenous Infusion, Hydration | Office | 92 | 33 | $22.80 | $2,098 |
| 96402 Chemotherapy Administration | Office | 71 | 28 | $27.84 | $1,976 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 63 | 60 | $13.04 | $822 |
| J3490 Unclassified drugs | Office | 59 | 17 | $0.56 | $33.31 |
| 96417 Chemotherapy Administration | Office | 55 | 19 | $51.79 | $2,849 |
By year: 2022 $1.7M for 109,486 services; 2023 $1.5M for 95,531 services; 2024 $1.5M for 87,945 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 16 | 12 | $8.65 | $138 |
Medicare prescription drug claims, 2024
In 2024, the drug William Gradishar prescribed most often to Medicare patients was Anastrozole, with 300 prescriptions and refills. In total William Gradishar wrote 687 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 300 | 842 | 97 | $6,967 |
| Tamoxifen Citrate Generic | 51 | 136 | 18 | $1,217 |
| Ibrance Palbociclib | 51 | 51 | Under 11 | $781K |
| Letrozole Generic | 49 | 148 | 17 | $1,296 |
| Exemestane Generic | 46 | 125 | 14 | $9,649 |
| Kisqali Ribociclib Succinate | 35 | 35 | Under 11 | $558K |
| Truqap Capivasertib | 24 | 24 | Under 11 | $401K |
| Verzenio Abemaciclib | 16 | 16 | Under 11 | $235K |
| Prochlorperazine Maleate Generic | 16 | 16 | Under 11 | $94.51 |
| Dexamethasone Generic | 12 | 12 | Under 11 | $202 |
| Orserdu Elacestrant Hcl | 12 | 12 | Under 11 | $267K |
Brand drugs: 169 claims; generic drugs: 518 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid William Gradishar $58K ($56K in general payments such as food, travel and fees and $2,022 for research) from 12 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $18K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 13 | $18K |
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $16K |
| F. Hoffmann-La Roche AG ROG.SW | 4 | $4,892 |
| Pfizer Inc. PFE | 1 | $4,675 |
| Gilead Sciences, Inc. GILD | 5 | $3,264 |
| Genentech, Inc. ROG.SW | 2 | $2,794 |
| Lilly USA, LLC LLY | 1 | $2,250 |
| Eli Lilly and Company LLY | 2 | $1,800 |
| Tolmar, Inc. | 1 | $1,800 |
| Janssen Research & Development, LLC JNJ | 3 | $1,292 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.